Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 19, 2009

DrStockPick.com Stock Report!

AMGN, PWRM, JNJ, CSRH, GE, CVAT, TEVA, AQNM

**************************************************************

AMGN, Amgen Inc.

AMGN, a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.

The Food and Drug Administration wants more information about AMGN’s osteoporosis treatment Prolia before granting marketing approval. It delays a drug seen as a potential blockbuster for the company.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of

Trading on the NASDAQ Capital Market, iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions. Headquartered in Nashua, New Hampshire, with additional offices in Beavercreek, Ohio, their solutions enable healthcare professionals to serve patients better by identifying pathologies and pinpointing cancer earlier. The Company’s solutions aid in the early detection of the most prevalent cancers.

The Company received Food and Drug Administration (FDA) approval of their first breast-cancer detection product in 2002. Since then they placed more than 2,700 iCAD systems in healthcare practices around the globe. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems, and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Their systems are for the high, mid, and low volume mammography markets.

iCAD’s mammography CAD innovations include being the first system to offer a clear film-to-digital upgrade path, as well as the

Interleukin Genetics, Inc., along with its subsidiaries, works to develop, acquire, and commercialize personalized health care products. Interleukin’s mission is to develop genetic tests and to make available therapeutic products that can help individuals improve and maintain their health through preventative measures. Interleukin genetics has a goal to provide the best available genetic information to help patients and consumers make intelligent lifestyle decisions related to nutrition, exercise, lifestyle habits, and healthcare practices aimed at preserving good health into old age.

The company wants to position itself at the forefront of the small but growing marketplace of personalized health. This segment is expected to experience rapid and widespread growth as genetic screening technologies become more available and affordable. This vision is grounded in the belief that the company can improve health outcomes by identifying individuals whose risk for certain chronic diseases is increased due to variants